- Nabil K El Naggar is Consultant Diabetologist& Head of Endocrine and Diabetes Center Fellow of the American College of Endocrinology Chairman of Jeddah Diabetes Club.AndJeddah Hypertension and Atherosclerosis Club.
- Nabil K El Naggar, Head of CME Committee of Hai AlJamea Hospital, Jeddah, SA.
- Nabil K El Naggar Graduated from Alexandria University on 1977, MSc Alexandria University 1982, ACA fellowship 1984, had IDF lifetime fellowship in 2004, and fellowship of American College of endocrinology in 2018.
- Member of many international organizations including ADA, AACE, EASD,AASD,ESC,BDA,ICA, fellow of the ISH, and life-member of IDF.
Has a lot of publications in international Journals and he is a reviewer/Editor of many Journals including :
- Annals of Diabetes Research Journal, Intervention in obesity & Diabetes Journal , EC Endocrinology and Metabolic Research, Journal.
- "Diabetic Medicine”:" Archives of Medical Research", "Diabetes Research And Clinical Practice",
- Journal of Family Medicine & CommunityHealth , Clinical Medicine Insights: Endocrinology and Diabetes,
- Libertas Academica, Journal of Diabetes & MetabolicDisorders, Endocrinology and Diabetes, Clinical Medicine Insights: Therapeutics ,
- BAOJ Obesity & Weight LossManagement Journal, and Issues in Biological Sciences and Pharmaceutical Research.
- Saied Khader , Waleed AbdelFattah , AbdulqawiAlmansari , Nabil K. Elnnagar. Safety and efficacy of switching to biphasic insulin aspart 30/70 (BIAsp 30) under the routine diabetic care in patients with type 2 diabetes:The IMPROVE™ observational study in the Gulf region. International Journal of Diabetes Mellitus. 2010;2:110–113.
- Philip Home , Nabil El Naggar , Mohammed Khamseh , Guillermo Gonzalez-Galvez, ChunduoShen , Praful Chakkarwar , et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Research and Clinical Practice. 2011;94:352-363.
- Philip Home, Siddharth N Shah, Guillermo Gonzaliz-Galves, Nabil K Elnaggar, Praful N Chakkarwar, Leon E Litwak. Starting Insulin Detemir in Older Versus Younger Adults with Type 2 Diabetes Mellitus : Results from the A1chieve Study. Presented at the American Diabetes Association, 8–12 June 2012, Philadelphia, PA, USA.
- Bassam Ben Abbas, MD, Waleed AbdelFattah, MD, Nabil el-Nagar, MD, Magdy Abdel Fattah Abdouand, MD, AbdulqawiAlmansari, MD, Diaa Mansour Ewais, MD.Insulin detemir: Safety and efficacy of treatment with insulin detemir in a population of people with diabetes (type 1 or type 2) in Saudi Arabia and the Gulf countries: An open label non-interventional study on people in routine clinical diabetes treatment (The Predictive Study. The Review of Diabetic Studies Hermansen, Lund, Clemmensen. 2007;4:2.
- Nabil El Naggar, Jihad Haddad, Rachid Malek, Zanariah Hussein, Jian–Wen Chen, WenyingYangImprovedglycaemic control in people with T2D switched from a glargine-based prandial insulin regimen to a basal-bolus regimen with insulin detemir and insulin aspart: A1chieve data. Presented in the EASD annual Meeting 2012, Berlin, Germany. Control/Tracking Number: A-12-548-EASD.Tracking Number: A-12-548-EASD.
- El Naggar N, Soewondo P, Khamseh ME, Chen J, Haddad J. Efficacy and safety of biphasic insulin aspart 30 in patients on prior biphasic human insulin: Data from A1chieve; a 24-week, international, prospective, multi-centre, open-labelled, non-interventional study. Under Publication.
- Starting Insulin Detemir in Older versus Younger adults with type 2Diabetes (T2DM): Results from the A1chieve Study. Poster Presentation at ADA 72nd meeting, 2012.
- Starting Insulin Aspart is Associated with Improvement in Quality of life Regardless of age. Naggar N, Home PD. Malek R, Latif ZA, Beck Bech OM, Goh SY.Oral Poster Presentation at IDF-WPR, Kyoto, Japan, 2012.
- Starting Insulin Aspart is Associated with Improvement in Quality of life Regardless of age. Naggar N, Home PD. Malek R, Latif ZA, Beck Bech OM, Goh SY.Oral Poster Presentation at ADA-ME, Dubai, 2012.
- El-Naggar N, Khudada K, Mariswamy N, El-Sayed H, Abdel Fattah W. Safety of Insulin Analogues in People with Type 2 Diabetes in the Gulf region: a Subgroup Analysis from the A1chieve Study. Presented in the 3rd World Conference of the Diabetes Asia Study Group (DASG) 2012.
- N. Elnaggar, A. AlMansari , K. Khudada, S. Salman, N. Mariswamy, W. AbdelFattah, F. HashimThe A1chieve Study- An Observational non-interventional Study of Type 2 Diabetes mellitus Initiating or switched to Insulin Analogues: Subgroup Analysis of the Gulf Population. Int J Clin Pract. 2013;67(2)128–138.
- Nabil El Naggar, Jihad Haddad, Rachid Malek, Zanariah Hussein, Jian–Wen Chen, Wenying Yang Improved glycaemic control in people with T2D switched from a glargine-based prandial insulin regimen to a basal-bolus regimen with insulin detemir and insulin aspart: A1chieve data. Under Publication.
- Factors Associated With Achieving Target HbA1c Levels in People with Type 2 Diabetes. Beginning Insulin DetemirTreatment: Findings from the A1chieve® Study. 1. Rachid Malek 2. Nabil El Naggar3. Jian-Wen Chen 4.Mohammad Imtiaz Hasan 5. PradanaSoewondo 6. Sei Hyun Baik 7. Philip Home. ADA, 2013. Poster 1595-P.
- Factors associated with achieving improved glycemic control : Findings from the observational A1chieve Study. Chuang LM, Chen J, Litwak L, El Naggar N, Guler S. ADA, 2013, Poster 960-P.
- Outcomes of switching from a glargine-based basal plus mealtime insulin regimen to biphasic insulin aspart 30 in people with type 2 diabetes. El Naggar N, et al. IDF 2013. Poster ME-2006.
- Switching from a glargine + mealtime multiple injection regimen to a mealtime + basal regimen with insulin detemir and insulin aspart in T2D. IDF 2013, Poster ME-1768.
- El-Naggar N, Almansari A, Khudada K, Salman S, Mariswamy N, Abdelfattah W, Hashim F: The A1 chieve study - an observational non-interventional study of patients with type 2 diabetes mellitus initiating or switched to insulin analogue therapy: subgroup analysis of the Gulf population. Int J Clin Pract. 2013;67(2):128-138.
- Elnaggar N. Diabetes and Hypertension : Review Article. J hypertension. 2014;3:6.
- Mourad elmourad, Nabil k. El Naggar, Yasser S. Sheta, Tony H. El Murr, FarhadFallahi, kavyanRazmjou, Michaela Scheiner, Wael Khattab . MENC (Middle East Neuropathy Council) Report on : Diabetic Peripheral Neuropathy. Modern Medicine (Middle East Edition). July,2015.
- Nabil El Naggar . Sanjay Kalra. Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus. Adv Ther. DOI 10.1007/s12325-016-0418-2.
- NABIL EL NAGGAR*, CHRISTOPHER H. SORLI, GREGORY FULCHER, ROOPA MEHTA, SØREN LINDBERG, LARS BARDTRUM, STEPHEN C. BAIN, Jeddah, KSA, Billings, MT, Sydney, Australia, Mexico City, Mexico, Virum, Denmark, Søborg, Denmark, Swansea, United KingdomReaching Individualized FPG Targets without Nocturnal Hypoglycemia with IDegAsp BID vs. BIAsp 30: A Meta-analysis. Oral poster in JUCED 11TH CONFERENCE, JEDDAH, SEPTEMBER 2017.
- Nabil K El Naggar. “Alpha Cell: New Understanding of Function”. EC Endocrinology and Metabolic Research ECO.01 (2019):01-02.
- Nabil Kamal Elnaggar, Mohamed Nabil Elnaggar, Alpha-cells: Its Role as the Islet Harmonizer, International Journal of Diabetes and Endocrinology. Special Issue: Hypoglycemia in Diabetes. Vol. 4, No. 4, 2019, pp. 104-107. doi: 10.11648/j.ijde.20190404.13.
